{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:16:13Z","timestamp":1789820173503,"version":"4.0.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb Co.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Simulations Plus, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>BMS-932481 was designed to modulate \u0263-secretase activity to produce shorter and less amyloidogenic peptides, potentially averting liabilities associated with complete enzymatic inhibition. Although it demonstrated the intended pharmacology in the clinic, BMS-932481 unexpectedly caused drug-induced liver injury (DILI) in a multiple ascending dose study characterized by dose- and exposure-dependence, delayed onset manifestation, and a high incidence of hepatocellular damage. Retrospective studies investigating the disposition and probable mechanisms of toxicity of BMS-932481 are presented here. These included a mass balance study in bile-duct-cannulated rats and a metabolite profiling study in human hepatocytes, which together demonstrated oxidative metabolism followed by biliary elimination as the primary means of disposition. Additionally, minimal protein covalent binding in hepatocytes and lack of bioactivation products excluded reactive metabolite formation as a probable toxicological mechanism. However, BMS-932481 and 3 major oxidative metabolites were found to inhibit the bile salt export pump (BSEP) and multidrug resistance protein 4 (MRP4) in vitro. Considering human plasma concentrations, the IC50 values against these efflux transporters were clinically meaningful, particularly in the high dose cohort. Active uptake into human hepatocytes in vitro suggested the potential for hepatic levels of BMS-932481 to be elevated further above plasma concentrations, enhancing DILI risk. Conversely, measures of mitochondrial functional decline in hepatocytes treated with BMS-932481 were minimal or modest, suggesting limited contributions to DILI. Collectively, these findings suggested that repeat administration of BMS-932481 likely resulted in high hepatic concentrations of BMS-932481 and its metabolites, which disrupted bile acid transport via BSEP and MRP4, elevating serum biomarkers of liver injury.<\/jats:p>","DOI":"10.1093\/toxsci\/kfad057","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T05:07:49Z","timestamp":1685596069000},"page":"235-245","source":"Crossref","is-referenced-by-count":8,"title":["Mechanistic investigation of liver injury induced by BMS-932481, an experimental \u0263-secretase modulator"],"prefix":"10.1093","volume":"194","author":[{"given":"Xiaoliang","family":"Zhuo","sequence":"first","affiliation":[{"name":"Pharmaceutical Candidate Optimization, Bristol Myers Squibb , Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett A","family":"Howell","sequence":"additional","affiliation":[{"name":"Simulations Plus, Inc. , Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[{"name":"Pharmaceutical Candidate Optimization, Bristol Myers Squibb , Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L","family":"Woodhead","sequence":"additional","affiliation":[{"name":"Simulations Plus, Inc. , Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Mosure","sequence":"additional","affiliation":[{"name":"Pharmaceutical Candidate Optimization, Bristol Myers Squibb , Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pharmaceutical Candidate Optimization, Bristol Myers Squibb , Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato J","family":"Scialis","sequence":"additional","affiliation":[{"name":"Nonclinical Disposition and Pharmacokinetics, Bristol Myers Squibb , Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaswamy","family":"Iyer","sequence":"additional","affiliation":[{"name":"Nonclinical Disposition and Pharmacokinetics, Bristol Myers Squibb , Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongnian","family":"Sun","sequence":"additional","affiliation":[{"name":"Automation and Assay Technologies, Bristol Myers Squibb , Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M","family":"Boy","sequence":"additional","affiliation":[{"name":"Small Molecule Drug Discovery, Bristol Myers Squibb , Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley A","family":"Lentz","sequence":"additional","affiliation":[{"name":"Pharmaceutical Candidate Optimization, Bristol Myers Squibb , Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Rex","family":"Denton","sequence":"additional","affiliation":[{"name":"Pharmaceutical Candidate Optimization, Bristol Myers Squibb , Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G","family":"Soars","sequence":"additional","affiliation":[{"name":"Pharmaceutical Candidate Optimization, Bristol Myers Squibb , Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M","family":"Johnson","sequence":"additional","affiliation":[{"name":"Pharmaceutical Candidate Optimization, Bristol Myers Squibb , Wallingford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Griffith","family":"Humphreys","sequence":"additional","affiliation":[{"name":"Pharmaceutical Candidate Optimization, Bristol Myers Squibb , Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"2023072808462864300_kfad057-B1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin. Pharmacol. Ther"},{"key":"2023072808462864300_kfad057-B2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Trial watch: phase ii and phase iii attrition rates 2011\u20132012","volume":"12","author":"Arrowsmith","year":"2013","journal-title":"Nat. Rev. Drug Discov"},{"key":"2023072808462864300_kfad057-B3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.toxlet.2004.08.009","article-title":"Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells","volume":"155","author":"Bova","year":"2005","journal-title":"Toxicol. Lett"},{"key":"2023072808462864300_kfad057-B4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/acsmedchemlett.8b00541","article-title":"Identification and preclinical evaluation of the bicyclic pyrimidine gamma-secretase modulator BMS-932481","volume":"10","author":"Boy","year":"2019","journal-title":"ACS Med. Chem. Lett"},{"key":"2023072808462864300_kfad057-B5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","article-title":"Drug-induced liver injury: interactions between drug properties and host factors","volume":"63","author":"Chen","year":"2015","journal-title":"J. Hepatol"},{"key":"2023072808462864300_kfad057-B6","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41598-021-81846-9","article-title":"Atorvastatin impairs liver mitochondrial function in obese Gottingen minipigs but heart and skeletal muscle are not affected","volume":"11","author":"Christiansen","year":"2021","journal-title":"Sci. Rep"},{"key":"2023072808462864300_kfad057-B7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/1751-2980.12684","article-title":"Serum biomarkers of drug-induced liver injury: current status and future directions","volume":"20","author":"Church","year":"2019","journal-title":"J. Dig. Dis"},{"key":"2023072808462864300_kfad057-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2014.09.005","article-title":"Quantitative NTCP pharmacophore and lack of association between DILI and NTCP inhibition","volume":"66","author":"Dong","year":"2015","journal-title":"Eur. J. Pharm. Sci"},{"key":"2023072808462864300_kfad057-B9","first-page":"289","article-title":"Effect of tricyclic drugs on mitochondrial membrane","volume":"39","author":"Eto","year":"1985","journal-title":"Acta Med. Okayama"},{"key":"2023072808462864300_kfad057-B10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nrd.2016.184","article-title":"Phase ii and phase iii failures: 2013\u20132015","volume":"15","author":"Harrison","year":"2016","journal-title":"Nat. Rev. Drug Discov"},{"key":"2023072808462864300_kfad057-B11","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury \u2013 types and phenotypes. Reply","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"2023072808462864300_kfad057-B12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/js970486q","article-title":"Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening","volume":"87","author":"Hop","year":"1998","journal-title":"J. Pharm. Sci"},{"key":"2023072808462864300_kfad057-B13","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.tiv.2011.12.016","article-title":"Evaluation of the novel in vitro systems for hepatic drug clearance and assessment of their predictive utility","volume":"26","author":"Houston","year":"2012","journal-title":"Toxicol. In Vitro"},{"key":"2023072808462864300_kfad057-B14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/ijms18051018","article-title":"Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis","volume":"18","author":"Iorga","year":"2017","journal-title":"Int. J. Mol. Sci"},{"key":"2023072808462864300_kfad057-B15","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.3390\/ijms22062954","article-title":"Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges","volume":"22","author":"Jee","year":"2021","journal-title":"Int. J. Mol. Sci"},{"key":"2023072808462864300_kfad057-B16","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cpt.1222","article-title":"Can bile salt export pump inhibition testing in drug discovery and development reduce liver injury risk? An international transporter consortium perspective","volume":"104","author":"Kenna","year":"2018","journal-title":"Clin. Pharmacol. Ther"},{"key":"2023072808462864300_kfad057-B17","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab. Dispos"},{"key":"2023072808462864300_kfad057-B18","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011213","article-title":"Notch signaling","volume":"4","author":"Kopan","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol"},{"key":"2023072808462864300_kfad057-B19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"key":"2023072808462864300_kfad057-B20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-200528040-00006","article-title":"Hepatic findings in long-term clinical trials of ximelagatran","volume":"28","author":"Lee","year":"2005","journal-title":"Drug Saf"},{"key":"2023072808462864300_kfad057-B21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/toxsci\/kfy253","article-title":"Quantitative systems toxicology analysis of in vitro mechanistic assays reveals importance of bile acid accumulation and mitochondrial dysfunction in TAK-875-induced liver injury","volume":"167","author":"Longo","year":"2019","journal-title":"Toxicol. Sci"},{"key":"2023072808462864300_kfad057-B22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40264-018-0642-6","article-title":"Liver safety of fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience","volume":"41","author":"Marcinak","year":"2018","journal-title":"Drug Saf"},{"key":"2023072808462864300_kfad057-B23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.21158","article-title":"Mrp4\u2212\/\u2212 mice have an impaired cytoprotective response in obstructive cholestasis","volume":"43","author":"Mennone","year":"2006","journal-title":"Hepatology"},{"key":"2023072808462864300_kfad057-B24","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3748\/wjg.15.804","article-title":"Bile acids: chemistry, physiology, and pathophysiology","volume":"15","author":"Monte","year":"2009","journal-title":"World J. Gastroenterol"},{"key":"2023072808462864300_kfad057-B25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxsci\/kft176","article-title":"A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development","volume":"136","author":"Morgan","year":"2013","journal-title":"Toxicol. Sci"},{"key":"2023072808462864300_kfad057-B26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cpt.564","article-title":"Drug-induced liver injury: advances in mechanistic understanding that will inform risk management","volume":"101","author":"Mosedale","year":"2017","journal-title":"Clin. Pharmacol. Ther"},{"key":"2023072808462864300_kfad057-B27","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1124\/dmd.109.027797","article-title":"A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding","volume":"37","author":"Nakayama","year":"2009","journal-title":"Drug Metab. Dispos"},{"key":"2023072808462864300_kfad057-B28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/toxsci\/kfx040","article-title":"Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury","volume":"163","author":"Otieno","year":"2018","journal-title":"Toxicol. Sci"},{"key":"2023072808462864300_kfad057-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2004.06.001","article-title":"Mitochondrially-mediated toxicity of bile acids","volume":"203","author":"Palmeira","year":"2004","journal-title":"Toxicology"},{"key":"2023072808462864300_kfad057-B30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/acs.chemrestox.8b00246","article-title":"Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs","volume":"32","author":"Rana","year":"2019","journal-title":"Chem. Res. Toxicol"},{"key":"2023072808462864300_kfad057-B31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tox.2014.05.009","article-title":"Mitochondria: the gateway for tamoxifen-induced liver injury","volume":"323","author":"Ribeiro","year":"2014","journal-title":"Toxicology"},{"key":"2023072808462864300_kfad057-B32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1124\/jpet.116.232256","article-title":"The gamma-secretase modulator, BMS-932481, modulates abeta peptides in the plasma and cerebrospinal fluid of healthy volunteers","volume":"358","author":"Soares","year":"2016","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"2023072808462864300_kfad057-B33","volume-title":"Mechanism of Action Assays for Enzymes","author":"Strelow","year":"2012"},{"key":"2023072808462864300_kfad057-B34","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/1087057113494807","article-title":"Development of novel, 384-well high-throughput assay panels for human drug transporters: drug interaction and safety assessment in support of discovery research","volume":"18","author":"Tang","year":"2013","journal-title":"J. Biomol. Screen"},{"key":"2023072808462864300_kfad057-B35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.116.232249","article-title":"Robust translation of gamma-secretase modulator pharmacology across preclinical species and human subjects","volume":"358","author":"Toyn","year":"2016","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"2023072808462864300_kfad057-B36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat. Rev. Drug Discov"},{"key":"2023072808462864300_kfad057-B37","volume-title":"Schiff's Diseases of the Liver","author":"Watkins","year":"2017","edition":"12th ed"},{"key":"2023072808462864300_kfad057-B38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/11586600-000000000-00000","article-title":"Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase iii clinical trials of rivaroxaban after total hip or knee replacement surgery","volume":"34","author":"Watkins","year":"2011","journal-title":"Drug Saf"},{"key":"2023072808462864300_kfad057-B39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41573-019-0048-x","article-title":"Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models","volume":"19","author":"Weaver","year":"2020","journal-title":"Nat. Rev. Drug Discov"},{"key":"2023072808462864300_kfad057-B40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fphar.2014.00240","article-title":"Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury","volume":"5","author":"Woodhead","year":"2014","journal-title":"Front. Pharmacol"},{"key":"2023072808462864300_kfad057-B41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/clpt.2014.158","article-title":"Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity","volume":"96","author":"Yang","year":"2014","journal-title":"Clin. Pharmacol. Ther"},{"key":"2023072808462864300_kfad057-B42","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.apsb.2012.10.004","article-title":"Preclinical experimental models of drug metabolism and disposition in drug discovery and development","volume":"2","author":"Zhang","year":"2012","journal-title":"Acta Pharm. Sin. B"},{"key":"2023072808462864300_kfad057-B43","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1021\/acs.molpharmaceut.8b01226","article-title":"Dissecting the contribution of OATP1B1 to hepatic uptake of statins using the OATP1B1 selective inhibitor estropipate","volume":"16","author":"Zhang","year":"2019","journal-title":"Mol. Pharm"},{"key":"2023072808462864300_kfad057-B44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1353\/pbm.1968.0004","article-title":"The spectrum of hepatotoxicity","volume":"12","author":"Zimmerman","year":"1968","journal-title":"Perspect. Biol. Med"}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfad057\/50710285\/kfad057.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/194\/2\/235\/50965738\/kfad057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/194\/2\/235\/50965738\/kfad057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T08:48:00Z","timestamp":1690534080000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/194\/2\/235\/7188119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,6,1]]},"published-print":{"date-parts":[[2023,7,28]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfad057","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"value":"1096-6080","type":"print"},{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,6,1]]}}}